“And so look, we expect a step up in Q4.”

In context

“o. Big quarter for us this past quarter, getting the FDA approval. We just announced this morning we did -- we completed our first cases in the U.S. in February earlier this month in Cleveland Clinic. We got more scheduled this week, got other centers and all the leading indicators of Hugo. And by the way, on those cases, we got great feedback in terms of how the system is performing and and its future opportunity in the U.S. market. The leading indicators are all positive in terms of the smooth case rate, procedure growth globally and utilization, they can both continue to be really strong. We watch those every week. I know the business watches it every day, I see them every week. And we're seeing a pretty meaningful step-up in installations around the world, especially as U.S. kicks in. And so look, we expect a step up in Q4. Now the surgical business is a big business, has some puts and takes. So you may not move the needle on the surgical business quite yet. But underneath the covers there, Hugo is growing and growing pretty fast now. And it will -- eventually, you'll see -- you'll start to see this move that big $6 billion business. But we like where we sit. Really excited about getting into the U.S. market and the reception that we're getting and the orders that we have. Ingrid Goldberg: Next question comes from Danielle Antalffy at UBS. Danielle Antalffy: Geoff, I was hoping you could talk a little bit more about how we should think about renal denervation, Simplicity and the market development that you're talking about? We've talked to some referring physicians who've been involved in renal denervation s”